Shots:
- The US FDA has granted IND clearance to HLX05-N, a biosimilar version of Erbitux (cetuximab) for the treatment of metastatic colorectal cancer (mCRC)
- HLX05-N is developed by Henlius in accordance with biosimilar guidelines in China, the EU, & the US, and showed high similarity to reference cetuximab in analytical & non-clinical comparative studies
- Cetuximab is an anti-EGFR monoclonal antibody that binds to EGFR, blocking ligand binding & signaling to inhibit proliferation, induce apoptosis, & suppress angiogenesis, while also mediating ADCC to enable immune cells to kill tumor cells
Ref: Henlius | Image: Henlius | Press Release
Related News: Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
